Earlier Autism Diagnosis Possible for Some Children Based on Metabolic Biomarkers in Blood, New Research Shows
Sep 6, 2018A paper by NeuroPointDX scientists, along with our collaborator Dr. David Amaral (University of California – Davis MIND Institute), published in Biological Psychiatry, is the first publication resulting from the Children’s Autism Metabolome Project (CAMP), the largest study of the metabolism of children with autism spectrum disorder. Thomas Frazier, Chief Scientific Officer of Autism Speaks,
Stemina to Present Poster at Teratology Society Annual Meeting
Jun 15, 2018Stemina’s Jessica Palmer to Present Poster at Teratology Society Annual Meeting Jessica Palmer, Stemina’s Associate Director of Toxicology, will present a poster at the Teratology Society Annual Meeting, held June 23-27, 2018 in Clearwater, Florida. Anyone interested in developmental toxicity assays is encouraged to attend. A Human Pluripotent Stem Cell-Based Assay Accurately Predicts the Developmental
Stemina Launches Cardiotoxicity Assay, Presents Sponsored Session, Poster at SOT’s Annual Meeting & ToxExpo 2018
Feb 20, 2018Stemina Launches Cardiotoxicity Assay, Presents Sponsored Session, Poster at SOT’s Annual Meeting & ToxExpo 2018 The Stemina team will attend the Society of Toxicology’s Annual Meeting and ToxExpo in San Antonio, Texas from March 11-15, 2018. We are excited to share information about our new cardiotoxicity assay, Cardio quickPredict, now commercially-available for the first time.
NeuroPointDX Announces Validation of First-Generation Autism Diagnostic Panel
Jan 18, 2018NeuroPointDX, the neurodevelopmental disorders division of Stemina Biomarker Discovery, has validated 12 metabolic subtypes of autism spectrum disorder. The diagnostic blood test for ASD will be available later this year. CEO Elizabeth Donley says, “This is a historic moment, not just for Stemina and NeuroPointDX, but for our knowledge and understanding of autism.” Read the
Stemina to Present a Poster at American College of Toxicology Annual Meeting
Oct 25, 2017Jessica Palmer, Stemina’s Associate Director of Toxicology, will present a poster at the American College of Toxicology’s 38th Annual Meeting, held November 5-8, 2017 in Palm Springs, California. Anyone interested in cardiotoxicity assays is encouraged to attend. Development of a Targeted Biomarker Assay to Predict Cardiotoxicity Potential Using Metabolomics and Human Induced Stem Cell-Derived Cardiomyocytes
Stemina Featured as an Innovative Madison-Area Business
Sep 27, 2017In collaboration with the Greater Madison Chamber of Commerce, the Wisconsin State Journal produced a special section to “highlight and explore innovation efforts.” Each company’s profile is written by its leader. Stemina’s CEO, Elizabeth Donley, penned our article and also graces the cover of the section. Read Stemina’s profile Explore other companies in the section
Stemina Biomarker Discovery Prepares to Commercialize Autism Diagnostic Products; Appoints New Board Member, Heiner Dreismann, PhD, Former Head of Roche Molecular Diagnostics
Aug 25, 2017Dr. Driesmann, a leader in the diagnostics industry, will guide Stemina’s commercialization strategy. Read the full press release.
Stemina’s Jessica Palmer to Present at Teratology Society Annual Meeting
Jun 14, 2017Jessica Palmer, Stemina’s Associate Director of Toxicology, will present at the Teratology Society’s 57th Annual Meeting, held June 24-28, 2017 in Denver. Anyone interested in developmental toxicity assays is encouraged to attend. Prediction of Developmental Toxicity Potential by In Vivo Exposures with a Biomarker-Based Human Pluripotent Stem Cell Assay This presentation is part of Platform
Stemina to Present Sponsored Session, Poster at SOT’s Annual Meeting & ToxExpo 2017
Feb 20, 2017Stemina Biomarker Discovery will be well represented at the Society of Toxicology’s 56th Annual Meeting and ToxExpo. In addition to participating in SOT as an exhibitor (booth 2506), Stemina’s Jessica Palmer, Associate Director of Toxicology, will present new research in two sessions: Poster session: Monday, March 13th | 9:30 AM – 12:45 PM | P331
NeuroPointDX Partners with Ovid Therapeutics to Identify Biomarkers for Angelman Syndrome
Feb 9, 2017Together, Ovid and NeuroPointDX will use metabolomics data to better understand the rare neuro-genetic disorder known as Angelman Syndrome. NeuroPointDX’s metabolomics technology will be used in Ovid’s phase 2 STARS trial of its drug candidate, OV101.
Stemina Presenting Poster at ACT 37th Annual Meeting, November 6–9, 2016
Oct 14, 2016Jessica Palmer will present a poster entitled “Human Pluripotent Stem Cell-Based Assay Predicts Developmental Toxicity Potential of ToxCast Chemicals” at the annual meeting of the American College of Toxicology in Baltimore. Poster Abstract: Worldwide initiatives to screen for toxicity potential among the thousands of chemicals currently in use require inexpensive and high-throughput in vitro models to
Stemina to Present at Use of Cardiomyocytes for the Assessment of Proarrhythmic Risk Conference October 25-26
Oct 14, 2016Jessica Palmer will present a poster entitled “Development of a Biomarker-Based Cardiotoxicity Assay using Human Pluripotent Stem Cell-Derived Cardiomyocytes” at the upcoming Use of Cardiomyocytes for the Assessment of Proarrhythmic Risk Conference in Arlington, Virginia. Poster Abstract: Cardiac safety is one of the leading causes of late-stage compound attrition in the pharmaceutical industry and accounts for 28% of
Stemina CEO Beth Donley to deliver welcome remarks at 64th Annual Chamber Dinner
Sep 27, 2016Stemina’s CEO, Beth Donley, will deliver the welcome remarks at the 64th Annual Greater Madison Chamber of Commerce Dinner to be held September 28, 2016 at the Monona Terrace. Ms. Donley currently serves as the Board Chair. For more information, follow the link below: Read More
Stemina receives exceptional rating from EPA on devTOX assay performance
Jun 3, 2016Stemina is proud to announce that it has received an exceptional rating from the US Environmental Protection Agency for its work under ToxCast. Stemina’s devTOX assay is the only human developmental toxicity assay. Stemina offers its stem cell based assay in both human embryonic and induced pluripotent cell culture formats. Excerpt from the Contractor Performance
Stemina to Present Poster at IMFAR 2016
May 13, 2016The International Meeting for Autism Research (IMFAR) will be held in Baltimore, Maryland May 11-14. Visit the Saturday morning poster session to view our poster, “Evidence for Metabolomic Phenotypes Based on Analysis of Plasma from the APP Cohort.”
US EPA Presents devTOXqp Data
Mar 31, 2016Thomas Knudsen of the US EPA presented data on Stemina’s devTOXqp assay at the 2016 Society of Toxicology annual meeting.
Visit Stemina at SOT’s ToxExpo 2016
Mar 1, 2016Stemina will sponsor a session at the 2016 SOT Annual Meeting titled “Practical Application of a Human Stem Cell Assay for Developmental Toxicity Testing.” The session is Tuesday from 3:00 to 4:00 in Room 211. Stemina’s poster titled “Combination of a Human Pluripotent Stem Cell and Zebrafish Assay to Predict the Developmental Toxicity of Chemicals”
Autism Blood Test on Horizon
Feb 26, 2016A University of Wisconsin—Madison spinoff is screening blood samples in an effort to develop a biologically based method to diagnose autism through its diagnostic biomarker division, NeuroPointDX.
Donley Named InBusiness Exec of the Year
Feb 18, 2016Stemina’s CEO, Beth Donley, is named Executive of the Year by Madison’s InBusiness Magazine.